Novavax proven effective in phase 3 trials

Available for over a year

It's another shot in the arm for the World's battle against coronavirus. Novavax says its vaccine was 89 percent effective in preventing COVID-19 in trials - and importantly it's the first to show strong protection against the UK variant. It also helped 60 per cent of people with the South African variant. We'll also look at the row between the European Union and pharmaceutical companies over delays to getting doses. In South Africa, Major Fatima Isaacs led a three year battle over her religious right to wear a headscarf in the army.